Story perspectives
Biotech's Bright Future: Major Investments and Innovations Ahead
1/14/2026
50 11
1 of 1
Story summary
- At the JPMorgan Healthcare Conference, optimism for 2026 in biotech is high.
- Mike Doustdar, CEO of Novo Nordisk, plans to expand the incretin market with Wegovy.
- AbbVie partnered with the administration led by President Donald Trump to lower drug prices and invest $100 billion.
- Bristol Myers Squibb aims to deliver up to 10 products by decade's end.
- Pfizer's Albert Bourla emphasized a strong commitment to obesity treatments after acquiring Metsera.
